US Patent
US7888364 — Pyridyl inhibitors of hedgehog signalling
Composition of Matter · Assigned to Curis Inc · Expires 2028-11-11 · 2y remaining
Vulnerability score
22/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects novel compounds with the general formula I that inhibit hedgehog signaling, useful for treating malignancies.
USPTO Abstract
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R 1 , R 2 , R 3 , R 4 , m and n are as described herein.
Drugs covered by this patent
- Erivedge (vismodegib) · Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.